×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic ...
Nature
Dear Editor,. Two different randomized controlled trials (RCTs) have compared, head-to-head, the efficacy and safety of Bruton tyrosine...
12 hours ago
FDA approves BeiGene's TEVIMBRA for oesophageal cancer
Home - GlobalData
FDA approves BeiGene's TEVIMBRA for oesophageal cancer.
2 days ago
BeiGene, AbbVie patent spat to get trial from USPTO appeals board (NASDAQ:BGNE)
Seeking Alpha
The USPTO Patent Trial and Appeal Board has decided to hold a trial in a patent dispute between BeiGene and AbbVie. Read more here.
1 day ago
With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners
Yahoo Finance
Key Insights Significantly high institutional ownership implies BeiGene's stock price is sensitive to their trading...
1 week ago
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
Business Wire
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability...
6 days ago
US FDA approves expanded use of BeiGene's blood cancer drug
Reuters
The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's combination drug to treat certain...
1 month ago
Why BeiGene is one of 2024's most innovative medicines and therapeutics companies
Fast Company
Headquartered in Cambridge, Massachusetts, with offices in Beijing and Basel, Switzerland, BeiGene is the maker of cancer drug Brukinsa,...
1 month ago
BeiGene finally snags FDA approval for PD-1 drug Tevimbra after long delay, Novartis breakup
Fierce Pharma
Twenty months after the FDA's original target decision date, BeiGene has finally received the FDA's go-ahead for its PD-1 inhibitor...
1 month ago
BeiGene Secures Fifth Approval for Brukinsa, Expands into Follicular Lymphoma
BioSpace
BeiGene's Brukinsa becomes the first BTK inhibitor approved for follicular lymphoma, the most common type of low-grade non-Hodgkin lymphoma.
1 month ago
BeiGene spin-out Pi Health raises $30m to uptick cancer trial enrolment
Clinical Trials Arena
BeiGene spin-out Pi Health raises $30m to uptick cancer trial enrolment. Originally operating as a subsidiary under BeiGene, Pi Health has...
1 month ago